-
公开(公告)号：EP2137313A2
公开(公告)日：2009-12-30
申请号：EP08718165.7
申请日：2008-03-25
IPC分类号： C12N15/11
CPC分类号： C12N15/1137 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/3515 , C12Y603/02019 , C12N2310/3521
摘要： The invention relates to a double-stranded ribonucleic acid (dsRNA) for treating human papilloma virus (HPV) infection. The dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an HPV Target gene selected from the human E6AP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HPV infection and the expression of the E6AP gene using the pharmaceutical composition; and methods for inhibiting the expression of the HPV Target genes in a cell.
-
2.发明授权
公开(公告)号：EP1799270B1
公开(公告)日：2013-02-13
申请号：EP05797892.6
申请日：2005-09-15
IPC分类号： C12N15/11 , C12N15/113 , A61K48/00
CPC分类号： C12N15/1135 , C12N15/111 , C12N15/113 , C12N15/1131 , C12N2310/111 , C12N2310/14 , C12N2310/152 , C12N2310/315 , C12N2310/3183 , C12N2310/321 , C12N2310/322 , C12N2310/33 , C12N2310/351 , C12N2310/3511 , C12N2310/3515 , C12N2310/53 , C12N2330/30 , C12N2310/3521
-
公开(公告)号：EP1635763B1
公开(公告)日：2012-08-08
申请号：EP04776396.6
申请日：2004-06-09
IPC分类号： C12N15/113
CPC分类号： C12N15/113 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/3517 , C12N2310/3521
摘要： Aspects featured in the invention relate to compositions and methods for inhibiting alpha-synuclein (SNCA) gene expression, such as for the treatment of neurodegenerative disorders. An anti- SNCA agent featured herein that targets the SNCA gene can have been modified to alter distribution in favor of neural cells.
-
4.发明公开
公开(公告)号：EP1942948A2
公开(公告)日：2008-07-16
申请号：EP06837005.5
申请日：2006-11-03
发明人： SAH, Dinah, Wen-Yee , FRANK-KAMENETSKY, Maria , GEICK, Anke , HADWIGER, Philipp , ROEHL, Ingo , TAN, Pamela , VORNLOCHER, Hans-Peter
CPC分类号： C12N15/1138 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3515 , C12N2310/3521
摘要： The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Nav1.8 gene (Nav1.8 gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the Nav1.8 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the Nav1.8 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Nav1.8 gene gene in a cell
-
5.发明公开
公开(公告)号：EP1841464A2
公开(公告)日：2007-10-10
申请号：EP06733815.2
申请日：2006-01-24
IPC分类号： A61K48/00
CPC分类号： C12N15/1136 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3515
摘要： The invention relates to compositions and methods for modulating the expression of Nogo-L or Nogo-R genes, and more particularly to the downregulation of Nogo-L or Nogo-R by chemically modified oligonucleotides.
-
6.发明公开COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF FACTOR V LEIDEN MUTANT GENE 有权组合物和方法因子V Leiden突变基因表达抑制
公开(公告)号：EP1945270A2
公开(公告)日：2008-07-23
申请号：EP06837014.7
申请日：2006-11-07
IPC分类号： A61K48/00
CPC分类号： C12N15/113 , A61K47/554 , A61K48/00 , C12N2310/14 , C12N2320/30
摘要： The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Factor V Leiden mutant gene (Factor V Leiden mutant gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the Factor V Leiden mutant gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the Factor V Leiden mutant gene using the pharmaceutical composition; and methods for inhibiting the expression of the Factor V Leiden mutant gene in a cell.
-
公开(公告)号：EP1802644A2
公开(公告)日：2007-07-04
申请号：EP05802154.4
申请日：2005-09-26
CPC分类号： C12N15/113 , A61K31/7105 , A61K31/718 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/3515 , C12N2310/3521
摘要： The invention relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the downregulation of apolipoprotein B by chemically modified oligonucleotides.
摘要翻译： 本发明涉及用于调节载脂蛋白B的表达的组合物和方法，并且更具体地涉及通过化学修饰的寡核苷酸下调载脂蛋白B.
-
8.发明公开
公开(公告)号：EP1799270A2
公开(公告)日：2007-06-27
申请号：EP05797892.6
申请日：2005-09-15
IPC分类号： A61K48/00
CPC分类号： C12N15/1135 , C12N15/111 , C12N15/113 , C12N15/1131 , C12N2310/111 , C12N2310/14 , C12N2310/152 , C12N2310/315 , C12N2310/3183 , C12N2310/321 , C12N2310/322 , C12N2310/33 , C12N2310/351 , C12N2310/3511 , C12N2310/3515 , C12N2310/53 , C12N2330/30 , C12N2310/3521
摘要： The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an anti-apoptotic gene, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of an apoptotic gene, such as a Bcl gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of an anti-apoptotic gene using the pharmaceutical composition; and methods for inhibiting the expression of an anti-apoptotic gene in a cell.
-
公开(公告)号：EP2023937B1
公开(公告)日：2011-10-12
申请号：EP07797577.9
申请日：2007-05-18
CPC分类号： C12N15/113 , C12N2310/14 , C12N2310/3515
摘要： The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an Aha gene (Aha1 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an Aha gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Aha1 expression and the expression of an Aha gene using the pharmaceutical composition; and methods for inhibiting the expression of an Aha gene in a cell.
-
10.发明公开
公开(公告)号：EP1941059A2
公开(公告)日：2008-07-09
申请号：EP06827135.2
申请日：2006-10-27
发明人： SAH, Dinah Wen-Yee , HADWIGER, Philipp , ROEHL, Ingo , BRAMLAGE, Birgit , TAN, Pamela , VORNLOCHER, Hans-Peter , BUMCROT, David
CPC分类号： C12N15/113 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/3515 , C12N2310/3521
摘要： The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell.
-
-
-
-
-
-
-
-
-
搜索结果
23 条记录 (耗时 0.024 秒)
